Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. G. Dickman, S. A. Hamidi, A. M. Szema, S. I. Said (Stony Brook, Northport, United States Of America). Pulmonary arterial hypertension (PAH) in mice lacking the vasoactive intestinal polypeptide (VIP) gene: morphometric evidence for vascular remodeling. Eur Respir J 2006; 28: Suppl. 50, 989

Member's Comments

No comment yet.

Related content which might interest you: Microarray analysis of pulmonary gene expression in mice lacking the vasoactive intestinal peptide (VIP) gene: confirmation of a role in asthma and pulmonary arterial hypertension (PAH) Source: Annual Congress 2006 - Cellular mechanisms of airway disease Year: 2006 Gene expression alterations in mice lacking the VIP gene are conducive to pulmonary arterial hypertension and pulmonary vascular remodeling Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 Serotonin transporter genes, pulmonary haemodynamics and pulmonary hypertension Source: Annual Congress 2005 - Scientific year in review Year: 2005 In a model of genetic pulmonary hypertension, VIP attenuates pulmonary vascular remodeling and right ventricular hypertrophy Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007 Expression of the serotonin 1b receptor in experimental pulmonary hypertension Source: Eur Respir J 2003; 22: 408-412 Year: 2003 Inhalation of vasoactive intestinal peptide in pulmonary hypertension Source: Eur Respir J 2008; 32: 1289-1294 Year: 2008 Over expression of endothelin-1 (ET-1) in lung fibroblasts (LFb) from patients with pulmonary arterial hypertension (PAH), evidence for loss of inhibitory control Source: International Congress 2016 – New findings in mucosal immunology Year: 2016 Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target Source: Eur Respir J 2011; 38: 1453-1460 Year: 2011 The vascular bed in COPD: pulmonary hypertension and pulmonary vascular alterations Source: Eur Respir Rev 2014; 23: 350-355 Year: 2014 IL-6 receptor overexpression in pulmonary arterial smooth muscle cells in idiopathic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 PDGF promotes pulmonary artery smooth muscle cell proliferation and migration in pulmonary arterial hypertension Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Pulmonary arterial hypertension phenotype in VIP knockout mice Source: Eur Respir J 2006; 28: Suppl. 50, 546s Year: 2006 Vasoactive intestinal peptide (VIP) markedly attenuates pulmonary hypertension in fawn-hooded rats Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology Year: 2005 Pulmonary hypertension: the science behind the disease spectrum Source: Eur Respir Rev 2012; 21: 19-26 Year: 2012 Single arterial occlusion to locate resistance in patients with pulmonary hypertension Source: Eur Respir J 2003; 21: 31-36 Year: 2003 Inhibition of the Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling Year: 2006 Pathobiology of pulmonary arterial hypertension Source: Eur Respir J 2002; 20: 1559-1572 Year: 2002 Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases Source: Eur Respir J 2008; 31: 343-348 Year: 2008 Expression of fetal genes in pulmonary arterial hypertension Source: Annual Congress 2005 - Pulmonary hypertension and fibrosis: novel mechanisms Year: 2005 Endothelial cell mechanics are altered in pulmonary arterial hypertension (PAH) Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011